Skip to main content

Table 2 Survival outcomes of irinotecan plus temozolomide in Ewing sarcoma

From: Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

First author

Survival rates

Median OS (Months)

Median PFS (Months)

Wagner

NA

NA

4.7

Anderson

NA

NA

5.5

Casey

NA

NA

8.3

Kurucu

1-year OS: 54.2% 1-year PFS: 44.4%

12 (range 6–57)

5.5 (range 2–57)

Palmerini

1-year OS: 55% (95% CI 39–70) 6-month PFS: 49% (95% CI 35–63)

NA

3.9 (range 1–29)

Salah

6-month PFS: 39%

14.1

3.8

  1. Abbreviations: OS Overall survival, PFS Progression-free survival, NA Data not available